Adjusted EBITDA came in at EUR 393 million, including a negative currency impact of EUR 24 million. Operating cash flow improved significantly to EUR 234 million, compared to EUR 151 million in the same period last year.

For the first half of 2025, adjusted EBITDA reached €750 million (H1 2024: EUR 763 million). Although total revenue was down due to adverse currency effects, higher prices and cost reductions successfully offset volume declines and inflationary pressures. A key strategic move was the signing of a binding agreement to sell Akzo Nobel India to the JSW Group, with completion expected in Q4 2025.

CEO Greg Poux-Guillaume commented: “Our focus on structural efficiency is delivering results. In a subdued market environment and despite strong currency headwinds, we’ve improved our profitability. The planned sale of Akzo Nobel India marks the beginning of our portfolio optimisation efforts.”

The company maintains its guidance and expects adjusted EBITDA to exceed EUR 1.48 billion for the full year 2025 (at constant currencies). For the mid-term, AkzoNobel is targeting an EBITDA margin above 16% and a return on investment between 16% and 19%, driven by organic growth and industrial excellence.